SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Comparing access to orphan medicinal products in Europe
2 references·1 citing·9 second hop
Comparing access to orphan medicinal products in Europe (2019)Comparing access to orphan medicinal prod…Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL) (2017)Recommendations from the Euro…Variation in Health Technology Assessment and Reimbursement Processes in Europe (2016)Variation in Health Technolog…Establishing a reasonable price for an orphan drug (2020)Establishing a reasonable pri…Why rare diseases are an important medical and social issue (2008)A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development? (2018)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries (2021)
this work references cited by second hop

References

  • 2016Variation in Health Technology Assessment and Reimbursement Processes in Europe122 cited
  • 2017Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)103 cited

Cited by

  • 2020Establishing a reasonable price for an orphan drug78 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work